Hismanal (astemizole) direct-to-consumer ads
Are running in many of the popular consumer magazines such as Time, Newsweek, and People. The two-page ad plus brief summary has the headline: "Good news for allergy sufferers: The first once-a- day non-drowsy allergy medicine." The ad, which was precleared by FDA, continues: "Now you can get 24-hour non-drowsy relief by taking one little tablet one time a day. Just ask your doctor about Hismanal." The other prescription nonsedating antihistamine, Marion Merrell Dow's Seldane, is usually taken twice daily. Janssen Pharmaceutica plans to run the ad through the allergy season.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth